Skip to main
PHAT
PHAT logo

Phathom Pharmaceuticals (PHAT) Stock Forecast & Price Target

Phathom Pharmaceuticals (PHAT) Analyst Ratings

Based on 8 analyst ratings
Strong Buy
Strong Buy 75%
Buy 13%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Phathom Pharmaceuticals Inc. is poised for continued commercial growth, driven by expanding its prescriber base, particularly among primary care providers treating the non-erosive gastroesophageal reflux disease (NERD) segment. The company reported significant increases in filled prescriptions for its product VOQUEZNA, reaching over 300,000 since launch and demonstrating a 110% growth from previous figures. Additionally, the 4Q24 revenue of $29.7 million exceeded expectations, bolstering management's confidence in positive outcomes from upcoming regulatory decisions and overall market expansion.

Bears say

Phathom Pharmaceuticals has faced substantial stock pressure primarily due to uncertainties regarding the patent exclusivity of its product, Voquezna, which is likely to persist and weigh on the stock’s performance. Financially, the company reported a decrease in cash reserves, ending the fourth quarter of 2024 with $297 million, down from $335 million in the previous quarter, indicating potential cash flow challenges. Additionally, anticipated softer revenues for the first quarter of 2025 due to seasonal headwinds and inventory fluctuations further contribute to a negative financial outlook, compounded by risks related to product performance and securing necessary funding for operations.

Phathom Pharmaceuticals (PHAT) has been analyzed by 8 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 13% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Phathom Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Phathom Pharmaceuticals (PHAT) Forecast

Analysts have given Phathom Pharmaceuticals (PHAT) a Strong Buy based on their latest research and market trends.

According to 8 analysts, Phathom Pharmaceuticals (PHAT) has a Strong Buy consensus rating as of Aug 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Phathom Pharmaceuticals (PHAT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.